Intellia Therapeutics, Inc.

In this update, we highlight recent news on Poseida Therapeutics' fully allogeneic CAR-T candidate for multiple myeloma (P-BCMA-ALLO1), Intellia's and...

CMN Weekly (16 February 2024) - Your Weekly CRISPR...

CMN Weekly

Feb. 16, 2024

Some of the best links we picked up around the internet

CMN Weekly (2 February 2024) - Your Weekly CRISPR...

CMN Weekly

Feb. 2, 2024

Some of the best links we picked up around the internet

Intellia Therapeutics Announces Publication of...

CMN Briefs

Feb. 1, 2024

Intellia Therapeutics shares interim clinical results from the Phase 1 portion of the ongoing Phase 1/2 trial of NTLA-2002 in hereditary angioedema...

Gene-Editing Tools: Delivery Methods and...

CMN Special

Jan. 22, 2024

Gene-editing systems, especially CRISPR-Cas9, have revolutionised genome editing, offering potential cures for genetic disorders, cancers, and other...

CMN Weekly (5 January 2024) - Your Weekly CRISPR...

CMN Weekly

Jan. 5, 2024

Some of the best links we picked up around the internet

Recent Clinical Updates From the Gene-Editing...

Nov. 22, 2023

In this article, we look at recent clinical updates from the gene-editing field. These updates include clinical data from Vor Bio's ongoing Phase 1/2a...

CMN Weekly (17 November 2023) - Your Weekly CRISPR...

Nov. 17, 2023

Some of the best links we picked up around the internet